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1. Introduction 
Pyrrole(Py)-imidazole(Im)(PI) polyamides are small synthetic molecules composed of 
aromatic rings of N-methylpyrrole and N-methylimidazole amino acids (Trauger et al., 
1996). Synthetic polyamides recognize and bind to specific nucleotide sequences in the 
minor groove of double-helical DNA with high affinity (Pilch et al., 1996). Various sequence-
specific DNA-binding PI polyamides have been developed to regulate gene expression by 
targeting the promoter regions of enhancer and transcription factor-binding elements in 
vitro (Murty et al., 2004). PI polyamides were first identified from duocarmycin A and 
distamycin A, which bind in the minor groove of DNA (Tao et al., 1999; Trauger et al., 1996). 
Sequence-specific DNA recognition by PI polyamide depends on the sequence of side-by-
side amino acid pairs. A pair of Py opposite Im targets the CG base pair, whereas Im 
opposite Py recognizes the GC base pair, and the Py/Py combination binds to both AT and 
TA base pairs (White et al., 1997). PI polyamides designed to bind to the transcription 
factors Ets-1, lymphoid-enhancer binding factor 1, and the TATAbox-binding protein DNA 
binding site have been shown to inhibit virus replication in isolated human peripheral blood 
lymphocytes (Dickinson et al., 1998).  
PI polyamides can easily enter into the nucleus and bind to chromosomal DNA. Many 
promising observation for gene therapy using PI polyamides have been reported. PI 
polyamide targeting rat transforming growth factor (TGF)-β1 has been reported to inhibit 
the expressions of TGF-β1 mRNA and protein in the renal cortex of Dahl-S rats. The targeted 
PI polyamide also reduced glomerulosclerosis and interstitial fibrosis without side effects. 
These observations indicate that PI polyamides will be effective for TGF-β1-related diseases, 
including progressive renal injury (Matsuda et al., 2011; Matsuda et al., 2006). PI polyamides 
targeting human aurora kinase-A (AURKA) and -B (AURKB) promoters significantly 
inhibited the promoter activities, and mRNA and protein expression levels of AURKA and 
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AURKB. They also demonstrated a marked antiproliferative synergy in human tumor cell 
lines as a result of induction of apoptosis-mediated severe catastrophe of cell-cycle 
progression (Takahashi et al., 2008). PI polyamides specifically inhibited lectin-like oxidized 
low-density lipoprotein receptor-1 mRNA expression and apoptosis induced by oxidized 
low-density lipoprotein and angiotensin II in human umbilical vein endothelial cells (Ueno 
et al., 2009). From these observations, PI polyamides have been identified as novel 
candidates for gene therapy. 
Pharmacokinetics is the science that studies the behavior of a circulating drug administered 
to a body, mainly focusing on absorption, distribution, metabolism, and excretion (ADME) 
of a drug (Jang et al., 2001). The concentration of a drug in a body can be obtained by a 
bioanalytical method which includes sample extraction and detection of a drug, and the 
obtained data are analyzed to evaluate the pharmacokinetics of the drug. Needless to say, a 
robust bioanalytical procedure is crucial for evaluating the appropriate pharmacokinetic 
profile of a drug. 
In this chapter, we show the bioanalytical procedure, pharmacokinetics, and modeling of PI 
polyamides A and B. PI polyamides A and B are illustrated in Fig. 1. PI polyamide A was 
composed of Ac-ImPyPy-ImPyPy-β-Dp (β, β-alanine; Dp, N, N-dimethylaminopropylamide). 
PI polyamide B was composed of Ac-PyPy-β-PyImPy-PyPyPy-β-ImPy-β-Dp. The molecular 
weights of PI polyamides A and B were calculated from the sum of the standard atomic 
weights of all the atoms (Wieser, 2006). The molecular weights of PI polyamides A and B are 
1035.12 and 1665.78, respectively. PI polyamide B was designed to bind to the activator 
protein-1 (AP-1)-binding site of the TGF-β1 promoter, whereas PI polyamide A also, with a 
hairpin structure, was designed for comparing with other types of PI polyamide with a hairpin 
structure and a higher molecular weight. 
 
 
Fig. 1. Chemical structures of PI polyamides A and B. 
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2. Bioanalytics 
High-performance liquid chromatography (HPLC) has been used for many years as a useful 
and conventional tool for the analysis of a drug. Bioanalytical methods by HPLC with UV 
detection were developed for the determination of PI polyamides A and B in the rat matrix. 
Sample extraction is one of the important steps and key to success in constructing a robust 
method. A simple protein precipitation method was developed for the extraction of PI 
polyamides A and B from rat plasma, whereas solid phase extraction was carried out to 
extract PI polyamides A and B from rat urine and bile, because a large number of urinary 
and biliary matrices can interfere with the compounds. It is important to determine the rates 
of urinary and biliary excretions because these excretions play pivotal roles in the 
elimination pathway of a drug. The developed methods were successively validated for 
selectivity, sensitivity, linearity, accuracy, and precision, following the guideline for 
Bioanalytical Method Validation published by Food and Drug Administration in 2001. 
Chromatographic separation was conducted using a reversed-phase TSK-GEL ODS-80TM 
(4.6 mm x 150 mm) column maintained at 40 ºC. The mobile phase of solvent A was 0.1% 
acetic acid and that of solvent B was acetonitrile (a linear increase from 0 to 80% B over 10 
min (plasma and urine) or 35 min (bile) and  an isocratic flow at 60% B for 5 min). The flow 
rate was set at 1.0 mL/min (plasma and urine) or 0.75 mL/min (bile). The detection 
wavelength was set at 310 nm. PI polyamides A and B were well separated from the 
coextracted material under the described chromatographic conditions at approximate 
retention times of 9.7 (25.0 in bile) and 10.5 min, respectively. The peak shapes were 
satisfactory and completely resolved from one another. No interference from rat matrices 
was observed (Fukasawa et al., 2007). 
 
 
Fig. 2. Representative chromatograms of blank rat plasma (A), blank rat urine (B) and blank 
rat bile (C) spiked with PI polyamide A, and blank rat plasma (D), blank rat urine (E) and 
blank rat bile (F) spiked with PI polyamide B. The concentrations of PI polyamides were 5 
(A), 20 (B), 1 (C), 5 (D), 20 (E) and 5 (F) µg/mL. 
Table 1 shows the intra- and inter-assay precision and accuracy of PI polyamides A and B. 
The intra- and inter-assay accuracies (RE) were within ± 20% for the lower limit of 
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quantitation (LLOQ) and ± 15% for the other QC samples. The intra- and inter-assay 
precisions (CV) were also within the acceptable ranges of 20% for the LLOQ and 15% for the 
other QC samples. The LLOQ was determined as 1 µg/mL for both PI polyamides A and B. 
All of the methods were successfully applied to evaluate the pharmacokinetics of the PI 
polyamides (Fukasawa et al., 2009; Fukasawa et al., 2007; Nagashima et al., 2009b). 
 
RE (%) CV (%) RE (%) CV (%)
Plasma PI polyamide A 1 2.2 5.3 6.7 14.4
20 1.4 1.4 -8.7 9.7
100 7.7 3.7 3.6 3.5
PI polyamide B 1 2.8 10.0 2.2 15.0
20 -2.5 0.6 -9.2 7.9
100 3.7 2.6 3.2 3.2
Urine PI polyamide A 1 13.4 1.2 4.6 7.9
20 -0.9 0.7 -4.7 3.6
200 0.4 0.3 -2.6 4.5
PI polyamide B 1 7.3 1.9 11.9 4.4
10 1.9 1.2 0.1 2.3
20 0.4 0.5 0.1 0.8
Nominal
concentration
(Ǎg/mL)
Intra-assay Inter-assay
Matrix
 
Table 1. Intra- and inter-assay accuracy and precision for the determination of PI 
polyamides A and B in rat plasma and urine. 
Although HPLC with UV detection is a useful tool for the determination of a drug, the 
sensitivity is a limitation factor for evaluating pharmacokinetic characteristic for many 
hours. Recently, liquid chromatography-tandem mass spectrometry (LC-MS/MS) has been 
used for the determination of a drug, especially when a sensitivity higher than that of HPLC 
is required. A bioanalytical method for the determination of PI polyamide A in rat plasma 
was successfully developed and validated by ultra-performance liquid chromatography 
(UPLC)-MS/MS with electrospray ionization (Nagashima et al., 2009a). 
An MS scan was conducted in the positive ion mode to obtain the precursor ion of PI 
polyamide A. The mass spectra of PI polyamide A showed significant ions at the m/z of 
1036, 519, and 346, which corresponds to [M+H]+, [M+2H]2+, and [M+3H]3+, respectively 
(Fig. 3). The doubly charged polyamide showed the highest sensitivity during ionization. 
The product ion spectra of the doubly charged PI polyamide A are shown in Fig. 4. The 
multiple reaction monitoring (MRM) transition was selected at the m/z of 519 and 288.  
Chromatographic separation was performed using an ACQUITY UPLC HSS T3 (1.8 µm, 
2.1×50 mm) column with an in-line filter and maintained at 40 ºC. The liquid flow rate was 
set at 0.3 mL/min. The mobile phase of solvent A was acetonitrile/water/acetic acid 
(5/95/0.1, v/v/v) and that of solvent B was acetonitrile/water/acetic acid (95/5/0.1, 
v/v/v). The gradient started at the mobile phase A-B (95:5%), changed linearly to A-B 
(45:55%) until 2 min, washed with A-B (0:100%) until 3.5 min, and equilibrated under the 
initial condition until 5.5 min. PI polyamide A was well separated from the coextracted 
material under the described conditions at an approximate retention time of 1.5 min. No 
interference from rat matrices was observed (Fig. 5).  
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Fig. 3. Representative mass spectra of precursor ions (m/z, 1036 [M+H]+, 519 [M+2H]2+, and 
346 [M+3H]3+) of PI polyamide A. 
 
 
Fig. 4. Representative product ion mass spectra (m/z, 519) of PI polyamide A. 
Table 2 shows the intra- and inter-assay precision and accuracy of PI polyamide A. The 
intra- and inter-assay accuracies (RE) were within ± 20% for the LLOQ and ± 15% for the 
other QC samples. The intra- and inter-assay precisions (CV) were also within the 
acceptable ranges of 20% for the LLOQ and 15% for the other QC samples. The LLOQ was 
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10 ng/mL, which means it has a sufficient sensitivity to evaluate the pharmacokinetics of PI 
polyamides.  
 
 
Fig. 5. Representative MRM chromatograms (m/z, 519>288) of (A) blank rat plasma, (B) 
blank rat plasma spiked with PI polyamide A (10 ng/mL). 
 
RE (%) CV (%) RE (%) CV (%)
10 -10.6 3.3 3.7 11.2
1000 -11.7 1.5 -2.1 9.2
10000 -0.6 4.6 -5.0 8.9
Nominal concentration
(ng/mL)
Intra-assay Inter-assay
 
Table 2. Intra- and inter-assay accuracy and precision for the determination of PI polyamide 
A in rat plasma. 
3. Pharmacokinetics of PI polyamides A and B 
3.1 Plasma and lung concentrations of PI polyamides A and B 
PI polyamide B significantly inhibited the expressions of TGF-β1 mRNA and protein in the 
renal cortex of the Dahl-S rats and reduced the rates of increases in the amounts of urinary 
protein and albumin in the Dahl-S rats independent of blood pressure at a dose of  
1.0 mg (Matsuda et al., 2006). From these observations, the doses of PI polyamides were 
selected on the basis of 1.0 mg dose of PI polyamide B per rat (about 3.0 mg/kg).  
PI polyamide B had a lower water solubility than PI polyamide A. The doses of PI 
polyamides A and B were determined to be in the ranges of 1.3-15.0 mg/kg and 1.0-5.0 
mg/kg, respectively. 
The mean plasma concentration-time profiles after the intravenous administration of PI 
polyamide A at 1.3, 2.0, 7.5, and 15.0 mg/kg and after that of PI polyamide B at 1.0, 2.0, 
3.0, and 5.0 mg/kg are shown in Fig. 6. The plasma concentrations of PI polyamides A 
and B declined in a polyexponential manner for the four doses studied. The plasma 
concentration-time profiles of PI polyamides were analyzed by a non-compartmental 
method. The area under the plasma concentration-time curve (AUC(0-Tlast)) and the area 
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under the first moment curve (AUMC(0-Tlast)) were obtained using the linear trapezoidal 
rule. AUC(Tlast-∞) and AUMC(Tlast-∞) were respectively calculated using Cn/ǌz and tnCn/ǌz + 
Cn/ǌz 2, where Cn is the last quantifiable concentration. Terminal-phase rate constant (ǌz) 
was calculated by the regression of the terminal log-linear portion of the plasma 
concentration curve. Terminal elimination half-life (t1/2) was calculated to be 0.693/ǌz. 
Systemic clearance (CLt), mean residence time (MRT), and the volume of distribution in 
the steady state (Vss) were calculated as dose/AUC, AUMC/AUC, and CLtMRT, 
respectively. The plasma concentrations of PI polyamides A and B were extrapolated to 
time zero (C0). The maximum plasma concentration (Cmax) of PI polyamide B was directly 
obtained from the observed data. 
 
 
Fig. 6. Mean plasma concentration–time profiles of PI polyamides in rats after intravenous 
administration. (A) and (B) show PI polyamides A and B.  
The pharmacokinetic parameters of PI polyamides A and B obtained in rats using non-
compartmental analysis are summarized in Table 3. After the intravenous administration of 
PI polyamide A at 1.3, 2.0, 7.5, and 15.0 mg/kg, the average t1/2, CLt, and Vss values were in 
the ranges of 42.3-74.8 min, 4.6-6.4 mL/min/kg, and 244-412 mL/kg, respectively. After the 
intravenous administration of PI polyamide B at 1.0, 2.0, 3.0, and 5.0 mg/kg, the average 
t1/2, CLt, and Vss values were in the ranges of 27.5-58.7 min, 7.3-11.9 mL/min/kg, and 407-
667 mL/kg, respectively. The CLt and Vss of PI polyamides A and B showed no significant 
differences as functions of administration dose. The pharmacokinetics of PI polyamides A 
and B are linear in the intravenous dose ranges of 1.3-15.0 mg/kg and 1.0-5.0 mg/kg, 
respectively as revealed by the fact that AUC increased linearly as a function of dose, and 
CLt and Vss remained unaltered.  
The plasma concentration-time profiles after the intravenous administration of PI polyamide 
B resembled those after the oral administration. After the intravenous administration of PI 
polyamide B at 1.0, 2.0, 3.0, and 5.0 mg/kg, Cmax gradually increased. The concentrations of 
PI polyamide B in the lungs, liver, heart, kidney and spleen were measured. The mean 
concentrations of PI polyamide B in the lungs were the highest among those in other tissues, 
and the mean concentrations 10, 30, and 60 min after injection were 134.7, 97.0, and 73.9 
µg/g, respectively. Among various tissues, the concentration of PI polyamide B was 
observed to be highest in the lungs. The mean lung concentration of PI polyamide B 
decreased with time. 
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PI polyamide A
1.3 mg/kg 2.0 mg/kg 7.5 mg/kg 15.0 mg/kg
Body weight (kg) 0.267 0.291 0.243 0.26
t1/2  (min) 54.8 42.3 74.8 45.3
C0 (Ǎg/mL) 14.1 22.9 77.1 227.5
AUC (Ǎg min/kg) 259.6 316.8 1528.6 3331.9
Cl (mL/min/kg) 5.6 6.4 5.1 4.6
Vss (mL/kg) 305.8 274.6 411.8 243.7
MRT (min) 68.1 42.6 80.5 54
PI polyamide B
1.0 mg/kg 2.0 mg/kg 3.0 mg/kg 5.0 mg/kg
Body weight (kg) 0.313 0.317 0.317 0.317
t1/2  (min) 139.1 165.8 207.3 359.3
C0 (Ǎg/mL) 1.5 4 3.8 4
AUC (Ǎg min/kg) 108.1 205.2 326.8 508.3
Cl (mL/min/kg) 9.9 8.9 9.2 10.3
Vss (mL/kg) 2170.5 1990.1 2602.2 4567
MRT (min) 194.7 222.5 289.7 492.1
Parameter
Dose
Parameter
Dose
 
Table 3. Mean non-compartmental pharmacokinetic parameters of PI polyamides after 
intravenous administration at various doses into rats (n = 3). 
3.2 Urinary and biliary excretions 
Determination of the urinary and biliary excretion rates is crucial for the evaluation of the 
pharmacokinetics of a drug, because drugs are usually eliminated from the body into urine 
and/or bile (Ullrich, 1997; van Montfoort et al., 2003). The urinary and biliary excretion rate-
time profiles are shown in Figs. 7 and 8, respectively. The urinary excretion rates of PI 
polyamides A and B showed a linear elimination. The biliary excretion rate of PI polyamide 
A showed saturation at the early period, while PI polyamide B was not detected in the bile. 
The cumulative urinary excretion rates of PI polyamides A and B at 48 h were 72.4 ± 11.6 
and 4.8 ± 0.5% (mean ± SD, n = 3) of the administered dose, respectively. The cumulative 
biliary excretion rate of PI polyamide A at 24 h was 4.3 ± 0.4% (n = 4) of the administered 
dose. These observations indicated that unchanged PI polyamides A and B were slowly 
eliminated from the body. As observed from the plasma concentration-time profile, it is 
considered that most of the PI polyamide B remained in the lungs. No peaks of metabolites 
were detected for all the samples. 
The differences in the molecular weights of compounds affect their eliminations (Hirom et 
al., 1976). The molecular weight thresholds for the excretion of organic cations into rat bile 
were found to be in the ranges of 200 ± 50 for monovalent organic cations and 500-600 for 
bivalent organic cations. (Hughes et al., 1973a; b) PI polyamide with a molecular weight of 
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1422.51 was excreted at 2% into rat urine 24 h after administration and was not detected in 
rat bile (data not shown). These findings suggested that PI polyamides with high molecular 
weights tend to be poorly excreted in both rat urine and bile, whereas those with molecular 
weights less than that of PI polyamide A can be readily eliminated. As described above, the 
differences in the elimination pathway between PI polyamides A and B may be attributed to 
the differences in their molecular weights. 
 
 
Fig. 7. Urinary excretion rate versus time profile of PI polyamides A (A) and B (B) in rats. 
 
 
Fig. 8. Biliary excretion rate versus time profile of PI polyamide A in rats. 
4. Pharmacokinetic modeling and simulations 
4.1 Pharmacokinetic modeling  
The plasma concentration-time profiles after the intravenous administration of PI polyamide 
A was fitted well by a two-compartment model. The estimated pharmacokinetic parameters 
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using the model are summarized in Table 4. After the intravenous administration of PI 
polyamide A at 1.3, 2.0, 7.5, and 15.0 mg/kg, the average CLt and Vss values were in the 
ranges of 4.9-7.0 mL/min/kg and 245-335 mL/kg, respectively. The CLt and Vss values 
estimated using a two-compartment model and a non-compartment model are thought to be 
identical. 
 
1.3 mg/kg 2.0 mg/kg 7.5 mg/kg 15.0 mg/kg
CLt (mL/min/kg) 5.8 7 5.8 4.9
Vss (mL/kg) 335 250 323 245
Vc (mL/kg) 90.5 89.6 96.6 69.7
Parameter
Dose
 
Table 4. Estimated pharmacokinetic parameters of PI polyamide A obtained using two-
compartment model. 
The plasma concentration-time profiles after the intravenous administration of PI polyamide 
B increased in the early phase and resembled those after the oral administration. The slope 
of the decline in the lung concentration-time profiles of PI polyamide B was nearly equal to 
that in the plasma concentration-time profiles of PI polyamide B. To describe the increasing 
phase of PI polyamide B after the intravenous administration, the lung and plasma 
concentration-time profiles of PI polyamide B were fitted using a catenary two-compartment 
model (Fig. 9) (Brown et al., 1981).  
 
 
Fig. 9. Pharmacokinetic model of PI polyamide B. 
C1, X1, and V1 represent the concentration of PI polyamide B in the lungs, the amount of PI 
polyamide B in the lungs, and the distribution volume of the lung compartment, 
respectively. C2, X2, and V2 represent the concentration of PI polyamide B in plasma, the 
amount of PI polyamide B in plasma, and the distribution volume of the plasma 
compartment, respectively. The pharmacokinetic parameters were calculated using the 
NONMEM program. 
Figure 10 shows the simulation curves for PI polyamide B based on the catenary two-
compartment model. The plasma and lung concentrations were fitted well by the model. 
The estimated pharmacokinetic parameters after the intravenous administration of PI 
polyamide B are summarized in Table 5. The estimated coefficients of variation (CV%) were 
small, the catenary two-compartment model better fitted the concentration-time profile after 
the intravenous administration of PI polyamide B. The model-estimated clearance (6.8 
mL/min/kg) calculated as k20 multiplied by V2 was nearly equal to CLt (7.3 mL/min/kg). In 
this study, lung concentrations of first-point were measured at 10 min. It is thought that the 
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concentration in the lungs immediately after the intravenous administration of PI polyamide 
B is higher than the calculated value. The early-plasma concentration-time profiles after the 
intravenous administration of a hairpin polyamide-chlorambucil conjugate, duocarmycin, 
and nitroglycerin are similar to that of PI polyamide B (Alberts et al., 1998; Chou et al., 2008; 
Wester et al., 1983) Recently, the biodistribution of a hairpin polyamide-chlorambucil 
conjugate administered into mice has been reported (Chou et al., 2008). The predominant 
occupancy of the polyamide-chlorambucil conjugate was observed in the lungs, spleen, 
small intestine, and pancreas 2 and 24 h after the injection. The concentration of polyamide-
chlorambucil conjugate in the lungs at 2 h was higher than that of the polyamide-
chlorambucil conjugate at 24 h. These findings are consistent with our results. PI polyamide 
B is distributed in the aorta and localizes in the nuclei of aortic midlayer smooth muscle 
(Matsuda et al., 2006). The lungs consist of pulmonary alveoli, which are surrounded by 
capillary vessels. It has been reported that weak basic drugs accumulate in the lungs and 
that such accumulation is attributable to lysosomal trapping (MacIntyre et al., 1988; Rodgers 
et al., 2005). A high concentration of PI polyamide B in the lungs was thought to be caused 
by PI polyamide B being distributed in capillary vessels of the lungs and by PI polyamide B 
being a weak base compared with PI polyamide with a molecular weight of 1422.51. It is 
also conceivable that PI polyamide B accumulated in the lungs owing to its high molecular 
weight, as suggested in a previous study (Wiseman et al., 2000). From these considerations, 
the proposed catenary two-compartment model may be applicable to describing PI 
polyamide B in detail. 
 
 
Fig. 10. Model fitted PI polyamide B concentration-time profiles in plasma and lungs. A is 
plasma concentration–time profiles and B is lung concentration-time profiles. The middle 
bold line indicates the 50th percentiles for 1000 simulations. Symbols depict the observed 
data after the intravenous administration of PI polyamide B at 3.0 mg/kg. 
4.2 Pharmacokinetic modeling with excretion data in addition to plasma concentration 
To predict the plasma concentration-time profile in the elimination phase of PI polyamide A 
after intravenous administration, two pharmacokinetic models (i.e., one- and two-
compartment models with the linear output compartment interpreted as the urine 
compartment and the non-linear output compartments interpreted as the bile compartment) 
using the plasma concentration-time profile and cumulative urinary and biliary excretion  
 
(min) 
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k12 (L/min) 0.0109
k20 (L/min) 0.1476
V1 (mL/kg) 20.88
V2 (mL/kg) 45.86
Parameter Estimates
 
Table 5. Pharmacokinetic parameters of PI polyamide B from model fitting. 
 
 
Fig. 11. Scheme of pharmacokinetic model describing the disposition and elimination of PI 
polyamides A (A) and B (B) 
rates of PI polyamide A were tested. A scheme of the two-compartment model, with the 
linear output compartment interpreted as the urine compartment and the non-linear output 
compartment interpreted as the bile compartment, is shown in Fig. 11A.  
X and V are the amount and volume of distribution in the corresponding compartments 
designated by the subscripts C, P, U, and B representing central, peripheral, urine, and bile 
compartments, respectively. CLD is the distribution clearance, CLR is the renal clearance, 
CLext is the clearance excluding renal and biliary clearances, VMAX is the maximum velocity 
for excretion into bile, and Km is the Michaelis constant for excretion into bile. Cc represents 
the plasma concentration of PI polyamide A. CU% and CB% represent the cumulative 
urinary and biliary excretion rates (percentage of administered dose), respectively.  
The residual error model of the plasma concentration was assumed to be the proportional 
error model because the plasma concentration was measured by HPLC. The model of the 
cumulative urinary and biliary excretions was assumed to be the additive error model 
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because the percentage of the administered dose was calculated from the urine and bile 
concentrations, urine and bile volumes, and administered dose. The choice of model was 
based on model fitting criteria such as visual inspection of the fitted curves, objective 
function value of NONMEM (OFV), and CV% of the parameter estimates (Hazra et al., 2007; 
Matsumoto et al., 2005).  
The plasma concentration and cumulative urinary and biliary excretion-time profiles after 
intravenous administration of PI polyamide A were fitted well by the two-compartment 
model with the linear output compartment interpreted as the urine compartment and the 
non-linear output compartment interpreted as the bile compartment (Fig. 12). The 50th 
percentiles of the model-based prediction for plasma concentrations and cumulative 
urinary and biliary excretions are presented together with the observed value. To obtain 
50th percentiles of the model estimations, 10000 simulations were performed using the 
estimated model parameters, variability in the estimated parameters, and residual 
variability of the data. Compared with a one-compartment model using only plasma data, 
more accurate data can be obtained from the two-compartment model including urine 
and bile data because PI polyamide A was excreted into urine and bile until at least 36 
and 18 h, respectively, after administration. The plasma concentration-time profile in the 
elimination phase could also be described better using both the linear and non-linear 
compartments than using plasma data only. 
 
 
Fig. 12. Plasma concentration–time profile (A), cumulative urinary excretion rate (B), and 
cumulative biliary excretion rate (C) of PI polyamide A after intravenous administration at 
2.0 mg/kg to rats. Each data point represents observed data from three (for plasma and 
urine) and four rats (for bile). The solid line indicates 50th percentiles from model 
estimations of 10000 simulations. 
To predict the plasma concentration-time profile in the elimination phase of PI polyamide B 
after intravenous administration, two pharmacokinetic models (i.e., one- and two-
compartment models with the linear output compartment interpreted as the urine 
compartment) using the plasma concentration-time profile and cumulative urinary 
excretions of PI polyamide B were tested. A scheme of the two-compartment model with the 
linear output compartment interpreted as the urine compartment is shown in Fig. 11B. The 
residual error models of the plasma concentration of PI polyamide B were the same as 
described in the part of PI polyamide A. 
The plasma concentration and cumulative urinary excretion-time profiles after intravenous 
administration of PI polyamide B were fitted well by the two-compartment model with the 
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linear output compartment interpreted as the urine compartment (Fig. 13). The 50th 
percentiles of the model-based prediction for plasma concentrations and cumulative urinary 
excretions are presented together with the observed value. To obtain 50th percentiles of the 
model estimations, 10000 simulations were performed using the estimated model 
parameters, variability in the estimated parameters, and residual variability of the data. 
 
 
Fig. 13. Plasma concentration–time profile (A) and cumulative urinary excretion (B) of PI 
polyamide B after intravenous administration at 2.0 mg/kg to rats. Each data point 
represents observed data from three rats (for plasma and urine). The solid line indicates 50th 
percentiles from model estimations of 10000 simulations. 
To predict the effective dose of PI polyamide B in Dahl-S rats administered at 1 mg every 2 
or 3 days for 4 weeks, pharmacokinetic simulations of PI polyamide B were performed 
using a slightly modified pharmacokinetic model (Nagashima et al., 2009b) by NONMEM 
program. The average plasma concentrations of PI polyamide B after the administration at 1 
mg every 3 and 2 days were 0.18 and 0.28 µg/mL, respectively, which were calculated by 
the area under the concentration-time curves between 0 and 27 days, divided by 27 days. PI 
polyamide B did not accumulate following multiple-dose administration. 
5. Conclusion 
PI polyamides show a remarkable potential for use in non viral gene therapy as many 
attractive results were obtained. The novel compounds could provide a promising impact 
on gene therapy for diseases not treatable by current remedies. To obtain the maximum 
therapeutic effect of the PI polyamide, it is crucial to evaluate the pharmacokinetics of the 
compounds for designing appropriate dosage regimens. Bioanalytical procedures for PI 
polyamides A and B were successfully developed and validated by HPLC or LC-MS/MS, 
and applied to sample assay. The pharmacokinetic profiles of PI polyamides show 
interesting results, which are thought to be related to their molecular weights (Brown et al., 
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1981). It was suggested that the features of various compositions of Py and Im were related 
to their unique pharmacokinetic profiles. Further examination will be conducted using other 
PI polyamides that have unique Py and Im combinations for gene therapy. 
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